药理定位PDIA1 抑制NLRP3炎症细胞组合和激活
Jessica D Rosarda1, Caroline R Stanton1,2, Emily B Chen1
1Department of Molecular and Cellular Biology, Scripps Research, La Jolla, CA 92037.
Israel journal of chemistry
|May 15, 2025
概括
蛋白质稳定调节剂AA147通过修改蛋白二硫化异构酶A1 (PDIA1) 来抑制NLRP3炎症体. 这一发现确定了PDIA1作为炎症性疾病的治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- NLRP3炎症酶对天生的免疫力至关重要,它调节炎症性细胞因子分泌.
- 它的过度活化与各种疾病有关,需要新的抑制策略.
研究的目的:
- 为了研究蛋白质稳定调节剂AA147作为NLRP3炎症酶组合和激活的抑制剂.
- 为了识别炎症体通路内的AA147的分子标.
主要方法:
- 利用单细胞和巨细胞来评估AA147对NLRP3炎症酶活性的影响.
- 研究了抑制的机制,专注于内分泌网膜 (ER) 蛋白质的修饰.
- 采用遗传衰竭和选择性抑制剂来验证已识别的目标的作用.
主要成果:
- AA147通过破坏炎症酶组合组合来抑制NLRP3炎症酶激活.
- AA147在ER膜上对蛋白质二硫化异构酶A1 (PDIA1) 进行共性修改.
- 通过遗传或化学手段抑制PDIA1,有效地阻止NLRP3炎症酶组合和激活.
结论:
- 确定PDIA1是NLRP3炎症酶组合和激活的关键调解者.
- 向PDIA1是一个有前途的治疗策略,用于控制各种疾病中的NLRP3炎症酶驱动的炎症.
相关概念视频
IP3/DAG Signaling Pathway
11.7K
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
11.7K
Parkinson's Disease: Treatment
163
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
163
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K
Regulation of the Unfolded Protein Response
2.3K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.3K


